Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 25;11(1):7.
doi: 10.3390/jcdd11010007.

Personalized Evidence-Based Management of Patent Ductus Arteriosus in Preterm Infants

Belinda Chan  1   2 , Yogen Singh  3   4
Affiliations
Review

Personalized Evidence-Based Management of Patent Ductus Arteriosus in Preterm Infants

Belinda Chan et al. J Cardiovasc Dev Dis. .

Abstract

There is no universal consensus on management of patent ductus arteriosus (PDA) in preterm infants and it varies significantly worldwide, even among the clinicians within units. The decision to treat requires a thorough understanding of the clinical status of the patient, clinical evaluation of PDA, echocardiographic diagnosis, and hemodynamic impact of ductal shunt on the pulmonary and systemic circulation. In this article, updated evidence on the efficacy and adverse effects of pharmacological treatment options and expectant management are presented, while highlighting the long-term benefits of PDA treatment remains equivocal and controversial. The authors propose a schematic targeted PDA treatment approach based on gestational and chronological age for practical clinical use, and they emphasize important future directions including advancement in PDA device closure techniques, diagnostic echo-parameters, hemodynamic evaluation to assess the impact on other organs, and understanding the long-term outcomes.

Keywords: ibuprofen; indomethacin; medical treatment; patent ductus arteriosus (PDA); premature infant; preterm infant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Arachidonic acid metabolism pathway.
Figure 2
Figure 2
PDA medical management strategy (adapted from 1 Semberova 2017 [17], 2 Sheppahrd 2018 (https://www.eyeonprivacy.com/2018/11/fda-issues-new-draft-cybersecurity-guidance-for-medical-devices/ (Accessed date 1 November 2023)) and 3 Hamrick 2020 [1]).
See this image and copyright information in PMC

References

    1. Hamrick S.E., Sallmon H., Rose A.T., Porras D., Shelton E.L., Reese J., Hansmann G. Patent ductus arteriosus of the Preterm infant. Pediatrics. 2020;146:e20201209. doi: 10.1542/peds.2020-1209. - DOI - PMC - PubMed
    1. Sung S.I., Chang Y.S., Kim J., Choi J.H., Ahn S.Y., Park W.S. Natural evolution of ductus arteriosus with noninterventional conservative management in extremely preterm infants born at 23–28 weeks of gestational age. PLoS ONE. 2019;14:e0212258. doi: 10.1371/journal.pone.0212256. - DOI - PMC - PubMed
    1. Benitz W.E. Committee on Fetus and Newborn; American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics. 2016;137:e20153730. doi: 10.1542/peds.2015-3730. - DOI - PubMed
    1. Dice J.E., Bhatia J. Patent ductus arteriosus: An overview. J. Pediatr. Pharmacol. Ther. 2007;12:138–146. doi: 10.5863/1551-6776-12.3.138. - DOI - PMC - PubMed
    1. El-Khuffash A., James A.T., Corcoran J.D., Dicker P., Franklin O., Elsayed Y.N., Ting J.Y., Sehgal A., Malikiwi A., Harabor A., et al. A patent ductus arteriosus severity score predicts chronic lung disease or death before discharge. J. Pediatr. 2015;167:1354–1361.e2. doi: 10.1016/j.jpeds.2015.09.028. - DOI - PubMed

LinkOut - more resources